Research Article Details
| Article ID: | A22050 |
| PMID: | 24850606 |
| Source: | Georgian Med News |
| Title: | [Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis]. |
| Abstract: | In a comparative aspect, the dynamics of indices of lipidogram, functional state of liver and level of C-reactive of protein have been analyzed in 79 patients with myocardial infarction in combination with non-alcoholic steatohepatitis, who received a 9-months treatment by rosuvastatin of 20 mg, atorvastatin of 80 mg, as well as rosuvastatin of 10 mg, atorvastatin of 40 mg in combination with ursodeoxycholic acid (UDCA). The obtained results show the equivalent of hypolipidemia effectiveness of all investigated courses of statinotherapy with the benefit of rosuvastatin of 20 mg in increase of level of HDL cholesterol and combined statinotherapy with UDCA in decrease of level of triglycerides. It was confirmed the significant advantages of combined statinotherapy with UDCA as for the influence on functional state of liver and CRP level, and advantages of rosuvastatin of 10 mg in combination with UDCA. Thus, the combination of rosuvastatin of 10 mg with UDCA should be preferable in the treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis from the positions of the effectiveness and safety. Besides, taking into account positive correlation between the CRP level in blood and activity of transaminases in the dynamics of observation it can be concluded that high activity of transaminases is the prognostic marker of the severity and procession of polymorbid pathology - myocardial infarction in combination with non-alcoholic steatohepatitis. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D312 | Rosuvastatin | Chemical drug | DB01098 | HMGCR inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D020 | Atorvastatin | Chemical drug | DB01076 | DPP4 inhibitor; AHR agonist; HDAC2 inhibitor; NR1I3 ligand | Enhance lipid metabolism | Under clinical trials | Details |
| D055 | Calcium | Chemical drug | DB01373 | CAST; COMP; CP; BMP4; MGP | -- | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D381 | Ursodeoxycholic acid | Chemical drug | DB01586 | AKR1C2 inducer | Anti-inflammatory | Under clinical trials | Details |